ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation

Cancer expression of PD-L1 suppresses anti-tumor immunity. PD-L1 has emerged as a remarkable therapeutic target. However, the regulation of PD-L1 degradation is not understood. Here, we identify several compounds as inducers of PD-L1 degradation using a high-throughput drug screen. We find EGFR inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Youqian, Zhang, Chao, Liu, Xiaolan, He, Zhengfu, Shan, Bing, Zeng, Qingxin, Zhao, Qingwei, Zhu, Huaying, Liao, Hongwei, Cen, Xufeng, Xu, Xiaoyan, Zhang, Mengmeng, Hou, Tingjun, Wang, Zhe, Yan, Huanhuan, Yang, Shuying, Sun, Yaqin, Chen, Yanying, Wu, Ronghai, Xie, Tingxue, Chen, Wei, Najafov, Ayaz, Ying, Songmin, Xia, Hongguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058344/
https://www.ncbi.nlm.nih.gov/pubmed/33879767
http://dx.doi.org/10.1038/s41467-021-22467-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058344/
https://www.ncbi.nlm.nih.gov/pubmed/33879767
http://dx.doi.org/10.1038/s41467-021-22467-8

Ejemplares similares